Pfizer, Inc. is a major pharmaceutical company. Its filings show it lobbies mainly on corporate and international tax rules, including U.S. Internal Revenue Code (IRC) sections and global tax changes tied to the OECD’s Pillar 1 and Pillar 2 agreements. It reported $230,000 across five filings and used The Washington Tax & Public Policy Group for this work.
Show the dominant industry call, how mixed the client looks, and the allocation across the top labeled sectors.
Annual totals based on disclosed filing amounts.
Issue rankings are based on disclosed activity mentions, with filing amounts apportioned evenly across issues within the same filing.
The lobbying registrants handling this client, ranked by disclosed filing amounts.
Lobbyists are ranked by appearances and an equal share of each filing's reported amount.
GREGORY NICKERSON
The latest disclosures for this client.
THE WASHINGTON TAX & PUBLIC POLICY GROUP
Q2THE WASHINGTON TAX & PUBLIC POLICY GROUP
Q1The entities named in disclosed activities are the clearest available signal for where the client is aiming attention.
THE WASHINGTON TAX & PUBLIC POLICY GROUP
ZACHARY AUSTIN PRICE
THE WASHINGTON TAX & PUBLIC POLICY GROUP
THE WASHINGTON TAX & PUBLIC POLICY GROUP
Q4THE WASHINGTON TAX & PUBLIC POLICY GROUP
Q3THE WASHINGTON TAX & PUBLIC POLICY GROUP
Q2THE WASHINGTON TAX & PUBLIC POLICY GROUP
Q1